89109-18-2

Basic information

• Product Name: 1,8-Naphthyridin-2(1H)-one, 1-phenyl-4-(2-propenyloxy)-
• CAS NO: 89109-18-2
• Molecular Formula: C17H14N2O2
• Molecular Weight: 278.31
• Mol File: 89109-18-2.mol

Chemical Properties

• CAS DataBase Reference: 1,8-Naphthyridin-2(1H)-one, 1-phenyl-4-(2-propenyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,8-Naphthyridin-2(1H)-one, 1-phenyl-4-(2-propenyloxy)-(89109-18-2)
• EPA Substance Registry System: 1,8-Naphthyridin-2(1H)-one, 1-phenyl-4-(2-propenyloxy)-(89109-18-2)

Safety Data

• Hazardous Substances Data: 89109-18-2(Hazardous Substances Data)

Upstream product

• 89109-17-1 4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one 
• 106-95-6 allyl bromide 
• 51269-84-2 methyl 2-phenylamino-nicotinate 
• 108-20-3 di-isopropyl ether 
• 115891-43-5 2-(N-acetylanilino)-3-carbomethoxypyridine 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 62-53-3 aniline 

Downstream Products

• 89108-58-7 4-acetyloxy-1-phenyl-3-(2-propenyl)-1,8-naphthyridin-2(1H)-one 

Relevant articles and documents

Tandem Claisen rearrangement and ruthenium catalyzed enyne bond reorganization as a route to the synthesis of tricyclic 1,8-naphthyridinones

A novel procedure for the synthesis of substituted 1,8-naphthyridinones via tandem Claisen rearrangement and ring-closing enyne metathesis is reported.

Synthesis of spiro-pyridopyridine analogues by Grubbs' catalyst mediated alkene and enyne metathesis reaction

A practical synthesis of spiro-naphthyridinone derivatives is described by the combination of the Claisen rearrangement and ring-closing metathesis/ring-closing enyne metathesis process. The RCM or RCEM proceeded smoothly in the presence of Grubbs' first

Antiallergy Agents. 1. Substituted 1,8-Naphthyridin-2(1H)-ones as Inhibitors of SRS-A Release

A novel class of antiallergy agents, the substituted 1,8-naphthyridin-2(1H)-ones, is described.The present compounds are orally active, potent inhibitors of allergic and nonallergic bronchospasm in animal models.Structure-activity studies of the lead compound in this sereis, 1-phenyl-3-n-butyl-4-hydroxynaphthyridin-2(1H)-one (11), identified three compounds of interest, 1-phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (12), 1-(3'-chlorophenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (87), and 1-(3'-methoxyphenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (89).The mechanism of antiallergy activity may involve inhibition of the release of the sulfidopeptide leukotrienes. 1-Phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one, Sch 33303 (12), was selected for preclinical development as an antiallergy agent.

Substituted 1,8-naphthyridinones, useful as anti-allergic agents

Substituted 1,8-naphthyridinones are anti-allergic, anti-inflammatory and cytoprotective agents. Methods for their preparation and use are disclosed.

1-Phenyl-1,8-naphthridin-2(1H)-ones

Certain substituted 1,8-naphthyridines and 1,5,8-azanaphthyridines are useful for treating allergic reactions in mammals. Certain of the compounds may also be utilized to treat chronic obstructive lung diseases in mammals. Methods for preparing the co

Composition containing 1-phenyl-1,8-naphthridin-2(1H)-ones and a non-steroidal anti-inflammatory drug

Certain substitute 1,8-naphthyridines and 1,5,8-azanaphthyridines are useful in treating and preventing ulcers in mammals. Methods for preparing the compounds and methods for their use are also described.